A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

Theriault, Richard L.; Walters, Ronald S.; Holmes, Frankie A.; Esparza-Guerra, Laura; Kowal, C.; Hortobágyi, Gabriel N.

doi:10.1007/s002800050484

Cited by 9 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single Phase II study has been reported for metastatic breast cancer, treated with 230 mg m -2 of sebriplatin once every 21 days. 77 Two partial responses were observed and several minor responses. Whilst the results indicated that further examination of that dose and schedule were not warranted, the authors hypothesised that the drug may be more efficacious at higher doses if colonystimulating factors were also used.…”

Section: Sebriplatinmentioning

confidence: 97%

“…Whilst the results indicated that further examination of that dose and schedule were not warranted, the authors hypothesised that the drug may be more efficacious at higher doses if colonystimulating factors were also used. 77 No other Phase II trial results have been reported in the literature. 78 with the same leaving group as carboplatin and a carrier ligand similar to zeniplatin (see below).…”

Section: Sebriplatinmentioning

confidence: 99%

See 1 more Smart Citation

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for\ud the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and\ud melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and\ud intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered\ud clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing\ud approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual\ud nations. During this time there have been more failures than successes with the development of 14 drugs\ud being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial\ud (satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has\ud entered clinical trials since 1999 which is representative of a shift in focus away from drug design and\ud towards drug delivery in the last decade. In this perspective article we update the status of platinum\ud anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued\ud during clinical trials, and discuss the results in the context of where we believe the field will develop over\ud the next decade

show abstract

Section: Sebriplatinmentioning

confidence: 97%

Section: Sebriplatinmentioning

confidence: 99%

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A phase II study on CI-973 (28) in 26 patients suffering from refractory advanced breast cancer was performed [87]. CI-973 had shown elevated antitumor activity against murine tumors and also cisplatin-resistant tumors in previous investigations and had been associated with lower side effects in phase I clinical trials [88][89][90].…”

Section: Single Agent Ci-973mentioning

confidence: 99%

Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue

Galanski

Keppler

2007

ACAMC

143

View full text Add to dashboard Cite

Cisplatin, carboplatin and oxaliplatin are anticancer drugs, which are efficiently used in the clinics all over the world. Besides a remarkable therapeutic efficacy in a series of solid tumors and outstanding activity of cisplatin against testicular germ-cell cancer, the platinum-based therapy is in part accompanied by a set of severe toxic side-effects. The design of platinum complexes being equipped with an exclusive selectivity for the tumoral tissue and exhibiting a lack of systemic toxicity ('magic bullets') is the great hope in the fight against cancer and also a motor within the expanding field of bioinorganic chemistry. In this review article, two promising strategies, namely accumulation and activation of tumor inhibiting platinum complexes specifically at the tumor site is presented, demonstrating a stepwise approach towards the 'magic bullet' concept propagated by Paul Ehrlich.

show abstract

“…Hematologic toxicity was severe with almost all patients having granulocytopenia, but no hospitalizations for neutropenic fever or infections were needed. Nonhematologic toxicities included nausea/vomiting, minimum peripheral paresthesia, fatigue and hypomagnesemia [27]. …”

Section: Experience With Single-agent Therapymentioning

confidence: 99%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

Cited by 9 publications

References 8 publications

The status of platinum anticancer drugs in the clinic and in clinical trials

The status of platinum anticancer drugs in the clinic and in clinical trials

Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Contact Info

Product

Resources

About